The Immediate Preoperative Anastrozole, Tamoxifen, or Combined With Tamoxifen (IMPACT) trial was designed to test the hypothesis that the clinical and/or biologic effects of neoadjuvant tamoxifen ...
Effects of Exemestane Administered for 2 Years Versus Placebo on Bone Mineral Density, Bone Biomarkers, and Plasma Lipids in Patients With Surgically Resected Early Breast Cancer Tamoxifen, which is ...
June 12, 2006 (Atlanta) — Women with breast cancer who are treated with the aromatase inhibitor anastrozole (Arimidex, AstraZeneca) for 5 years can lose 6% to 7% in bone-mineral density (BMD), enough ...
AstraZeneca Launches New Digital Resources for ARIMIDEX® (anastrozole) Tablets to Help Educate Patie
WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca (NYS: AZN) today launched new digital resources to educate patients on how to enroll in ARIMIDEX Direct. Resources include a "how to" video outlining ...
The news that the U.K. has approved a preventive drug for post-menopausal women at risk of developing breast cancer wasn’t a shock to breast medical oncologist Abenaa Brewster. But the fact that a ...
NEW YORK (Reuters Health) - After approximately 8 years, postmenopausal women with hormone-sensitive breast cancer who received (Arimidex), generically known as anastrazole, had a lower risk of ...
The United Kingdom’s Medicines and Healthcare products Regulatory Agency recently approved anastrozole as a treatment for preventing breast cancer in postmenopausal women at medium or high risk of ...
Studying the possible association between AI and cognitive dysfunction has accelerated over the past 7 years. A pilot study using neuropsychological testing from the Arimidex, Tamoxifen, Alone or in ...
CHICAGO, Dec 14 (Reuters) - Women who took AstraZeneca Plc's breast cancer drug Arimidex fared better than those who took the pill tamoxifen even four years after they stopped taking it, researchers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results